This site is intended for health professionals only!

Viramune® approved in EU for HIV-1 treatment

teaser

Viramune® (nevirapine) prolonged-release has received approval for use in the EU in combination with other antiretroviral medications for the treatment of HIV-1 infection.

EU approval for the use of one 400 mg tablet once daily for adults and adolescents – and for 50 mg and 100 mg strengths for once-daily treatment of children – is based on results from clinical trials confirming the significant therapeutic benefits of nevirapine when administered in a convenient once-a-day formulation.

The Viramune® XR™ single 400 mg tablet once daily was approved in the USA by the Food and Drug Administration earlier this year.

In clinical trials, the antiviral efficacy of Viramune® prolonged-release tablets was shown to be non-inferior to the older, twice-daily immediate-release (IR) 200mg tablet, with a safety and tolerability profile comparable to nevirapine IR.

“Nevirapine prolonged-release provides physicians and patients with a simplified, once-daily treatment while maintaining the high level of efficacy, comparable tolerability and favourable lipid profile already associated with the nevirapine immediate-release formulation,” said Dr Keikawus Arastéh, Director of Internal Medicine at Vivantes Auguste-Viktoria-Klinikum in Berlin, Germany.

“Switching therapies and a low pill burden can improve treatment adherence, which is often key to treatment success.”

Boehringer Ingelheim



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine